跳至主要内容
临床试验/NCT06083909
NCT06083909已完成不适用

Sarcopenic Obesity as Risk Factor for Insulin Resistance in the Elderly

University of Central Florida1 个研究点 分布在 1 个国家目标入组 97 人开始时间: 2022年4月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
97
试验地点
1
主要终点
To explore the correlation of sarcopenia and obesity on insulin resistance

研究概览

简要总结

Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • This study will include both male and females aged 65-85 years.

排除标准

  • Lack capacity to consent for the study, or have moderate or severe cognitive impairment;
  • Have difficulty ambulating as evidenced by any one of the following:
  • Difficulty climbing 10 steps without resting;
  • Restricted to a wheelchair
  • Have difficulty performing basic activities of daily living;
  • Have had treatment for cancer in the prior 3 years;
  • Have history of cachexia;
  • Have a history of heart failure;
  • Have a permanent pacemaker in situ (due to magnetic resonance scanning);
  • Have an implanted cardioverter-defibrillator (ICD) in situ;
  • Have had myocardial infarction within the last 6 months;
  • Have any of the following chronic health conditions: peripheral arterial disease prostate cancer, rheumatoid arthritis, autoimmune myositis, chronic obstructive pulmonary disease, and asthma;
  • Are receiving therapy with corticosteroids or immunosuppressants.
  • Are taking direct insulin sensitizers (PPAR-gamma agonists, or thiazolidinediones).

结局指标

主要结局

To explore the correlation of sarcopenia and obesity on insulin resistance

时间窗: 2 years

次要结局

  • To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.(2 years)
  • To explore the correlation between muscle strength and memory loss(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验